The global hemophilia market was valued at around USD 11.10 billion in 2019 and is anticipated to expand at a CAGR of around 5.6% during the forecast period, 2020 – 2026.
Availability of limited treatment therapy options and the growing burden on the regulatory bodies towards its treatment results in increasing R&D efforts. In addition, rising awareness campaigns and supportive initiatives plan by the government to commence early screening of neonates, which is expected to boost the requirement of diagnostic tools related to hemophilia.
Based on the data published by the WFH (World Federation of Hemophilia), hemophilia is more recorded among males and approximately 1 in 5,000 neonates suffer from type A. This is a rare genetic bleeding disorder projected to have affected around 440,000 people worldwide in 2018.
Increasing prevalence of bleeding disorders and growing severity with the genetic evolution globally is anticipated to drive overall market growth. Agencies like hemophilia Association of America generally offers continuous treatment for patients by introducing different co-pay initiatives.